Biotech Values

[DewDiligence]

MNTA:

…with the market environment nowadays, especially in the speculative developmental biotech sector, a best-case scenario FDA decision with m-enox in 2009 might give us a Vanda-like spike. Who knows what the market psychology will be in 2010. Maybe in 2010 we see smaller fireworks, but fireworks nonetheless!

No need to worry unduly—in the best-case scenario where MNTA/NVS’ Lovenox ANDA is approved and the other Lovenox ANDA’s aren’t, MNTA’s share price won’t need any help from bullish market psychology.

Inasmuch as a single generic Lovenox would easily be the largest-selling generic drug of all time and MNTA’s share of the net profits would be about 45%, simple cerebral calculations without any boost from exuberant emotions should be sufficient to do the trick.

For anyone who hasn’t run the numbers, please see #msg-37875396.